These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32843425)

  • 21. HiJAKing T-ALL.
    Asnafi V
    Blood; 2014 Nov; 124(20):3038-40. PubMed ID: 25395141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK3: a two-faced player in hematological disorders.
    Cornejo MG; Boggon TJ; Mercher T
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2376-9. PubMed ID: 19747563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Nairismägi M-; Gerritsen ME; Li ZM; Wijaya GC; Chia BKH; Laurensia Y; Lim JQ; Yeoh KW; Yao XS; Pang WL; Bisconte A; Hill RJ; Bradshaw JM; Huang D; Song TLL; Ng CCY; Rajasegaran V; Tang T; Tang QQ; Xia XJ; Kang TB; Teh BT; Lim ST; Ong CK; Tan J
    Leukemia; 2018 May; 32(5):1147-1156. PubMed ID: 29434279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
    Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
    Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
    Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
    J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
    Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
    Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
    Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
    Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
    de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
    Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].
    Xu PP; Zhou T; Xu YY; Peng MX; Du Y; Xie T; Yang YG; Ouyang J; Chen B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):872-875. PubMed ID: 39414615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
    Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
    J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
    Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
    Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.
    Brandimarte L; Pierini V; Di Giacomo D; Borga C; Nozza F; Gorello P; Giordan M; Cazzaniga G; Te Kronnie G; La Starza R; Mecucci C
    Blood; 2013 Jun; 121(25):5064-7. PubMed ID: 23673860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
    Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
    Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
    Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
    Hanna DM; Fellowes A; Vedururu R; Mechinaud F; Hansford JR
    Haematologica; 2014 Sep; 99(9):e156-8. PubMed ID: 24837469
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.
    Kawashima-Goto S; Imamura T; Seki M; Kato M; Yoshida K; Sugimoto A; Kaneda D; Fujiki A; Miyachi M; Nakatani T; Osone S; Ishida H; Taki T; Takita J; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Hosoi H
    Int J Hematol; 2015 Apr; 101(4):411-6. PubMed ID: 25430085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
    Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
    Batista CR; Lim M; Laramée AS; Abu-Sardanah F; Xu LS; Hossain R; Bell GI; Hess DA; DeKoter RP
    Blood Adv; 2018 Nov; 2(21):2798-2810. PubMed ID: 30355579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.